Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis

Experimental and Molecular Medicine

Volumn 48, Issue 2, 2016, Pages

  Park, Yune Jung ^a,b   Yoo, Seung Ah ^b   Hwang, Daehee ^c   Cho, Chul Soo ^b,d   Kim, Wan Uk ^b,e  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Institute for Basic Science   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELSOLIN; LYMPHOCYTE ANTIGEN; OROSOMUCOID; OROSOMUCOID 1; OROSOMUCOID 2; SOLUBLE CD14 ANTIGEN; UNCLASSIFIED DRUG; ORM2 PROTEIN, HUMAN; PROTEOME;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; URINALYSIS; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; PROTEOMICS; SEVERITY OF ILLNESS INDEX; URINE;

ARTHRITIS, RHEUMATOID; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; OROSOMUCOID; PROGNOSIS; PROTEOME; PROTEOMICS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84978639970     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2015.120     Document Type: Article

References (28)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.
2. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008; 67: 260-265.
3. Böttiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. Br Med J 1967; 2: 85-87.
4. Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991; 34: 1065-1068.
5. Pincus T, Braun J, Kavanaugh A, Smolen JS. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care. Clin Exp Rheumatol 2014; 32: S-1.
6. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1731-1736.
7. Watson L, Beresford MW. Urine biomarkers in juvenile-onset SLE nephritis. Pediatr Nephrol 2013; 28: 363-374.
8. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010; 26: 150-171.
9. Kang MJ, Park YJ, You S, Yoo SA, Choi S, Kim DH, et al. Urinary proteome profile predictive of disease activity in rheumatoid arthritis. J Proteome Res 2014; 13: 5206-5217.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
12. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 261-263.
13. Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1562-1568.
14. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 1993; 91: 207-213.
15. Yu S, Nakashima N, Xu BH, Matsuda T, Izumihara A, Sunahara N, et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 1998; 17: 237-243.
16. Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998; 57: 533-539.
17. Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. Am J Med 1997; 103: 12s-18s.
18. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 196-201.
19. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 1473-1477.
20. Smolen J, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
21. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, et al. Urine in clinical proteomics. Molecular & cellular proteomics. Mol Cell Proteomics 2008; 7: 1850-1862.
22. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177: 361-368.
23. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361.
24. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-R806.
25. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-257.
26. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012; 64: 640-647.
27. Puttevils D, De Vusser P, Geusens P, Dens J. Increased cardiovascular risk in patients with rheumatoid arthritis: an overview. Acta Cardiol 2014; 69: 111-118.
28. Goodman SM, Mackenzie CR. Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery. Curr Rheumatol Rep 2013; 15: 354.